Allahabad HC: Victim Compensation under POCSO Act Cannot be Withheld For Lack of Injury Report || MP HC: Diverting Goods From Delivery Point is Misappropriation under S.407 IPC || Delhi HC: Bar Associations are Not ‘State’ under Article 12 as They Do Not Perform Public Functions || Delhi HC: Pending Probate Proceedings Do Not Prevent Filing FIR For Alleged Will Forgery || Ker HC: Dismissal For Default Alone Cannot Justify Rejecting Restoration Plea For Lack of Vigilance || SC: Disclosure Statements Alone Cannot Secure Conviction Without a Complete Chain of Evidence || Supreme Court Orders Reporting of Student Suicides and Bans Denial of Classes or Exams || SC: Govt Can Exclude Overqualified Candidates From Posts Requiring Lower Qualifications || SC: Contracts to Hire Global Speakers For Media Summits are Not Taxable as Event Management Services || SC: Mandatory Injunction Suit Alone is Not Maintainable When Plaintiff’s Title is Disputed

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :